Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...

However, Vertex remains an attractive stock. Since that setback, the biotech has earned approval for Alyftrek, a next-generation medicine in its core area of expertise, cystic fibrosis (CF).

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its ...

Alyftrek's launch is considered the second most crucial factor for Vertex's stock performance in 2025, following Journavx. Management has noted early interest from three groups of potential ...

We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its portfolio, and is focused on delivering strong commercial launches of Alyftrek and Journavx.

The company still has plenty of room to grow in the CF market, especially with its recently approved drug Alyftrek. Not only is Alyftrek more effective than Vertex's top-selling Trikafta ...